Mantle D, Falkous G, Ishiura S, Blanchard P J, Perry E K
Dept of Neurochemistry, Regional Neurosciences Centre, Newcastle General Hospital, Newcastle upon Tyne, UK.
Clin Chim Acta. 1996 May 30;249(1-2):129-39. doi: 10.1016/0009-8981(96)06282-1.
Neuronal death associated with plaque and tangle formation characteristic of Alzheimer's disease (AD) may result from an underlying defect of intracellular protein catabolism. In an attempt to identify the proteolytic enzyme types responsible for aberrant protein processing, we have composed the levels of activity of proline endopeptidase in brain tissue samples (grey/white matter) from frontal, parietal, temporal and occipital lobes, from normal control cases, and cases with AD, Lewy body dementia (LBD), Parkinson's disease (PD) and Huntington's disease (HD). The activity of proline endopeptidase was significantly reduced in AD to approximately 65% of that of corresponding control tissue-this is of note since previous biochemical analyses have in general failed to detect altered activity of other protease types in AD tissues. However, this relatively selective reduction in proline endopeptidase activity in AD tissue (in terms of protease types investigated) is not specific for disease type, since activity was also reduced (65%-70% of control) in tissue samples from LBD, PD and HD cases. The data suggest that reduction in proline endopeptidase activity may be a characteristic of a generalized process of neurodegeneration. Although the precise cellular function of this enzyme in normal/ pathological tissues remains to be determined, the question arises as to whether pharmacological strategies designed to enhance proline endopeptidase activity in brain tissue may improve patient outcome in the above disorders.
与阿尔茨海默病(AD)特有的斑块和缠结形成相关的神经元死亡可能源于细胞内蛋白质分解代谢的潜在缺陷。为了确定负责异常蛋白质加工的蛋白水解酶类型,我们测定了来自额叶、顶叶、颞叶和枕叶的脑组织样本(灰质/白质)中脯氨酸内肽酶的活性水平,这些样本来自正常对照病例以及患有AD、路易体痴呆(LBD)、帕金森病(PD)和亨廷顿病(HD)的病例。AD患者脑中脯氨酸内肽酶的活性显著降低,约为相应对照组织的65%——这一点值得注意,因为以往的生化分析总体上未能检测到AD组织中其他蛋白酶类型的活性改变。然而,AD组织中脯氨酸内肽酶活性的这种相对选择性降低(就所研究的蛋白酶类型而言)并非疾病类型所特有,因为LBD、PD和HD病例的组织样本中该酶活性也降低了(为对照的65% - 70%)。数据表明脯氨酸内肽酶活性降低可能是神经退行性变这一普遍过程的一个特征。尽管该酶在正常/病理组织中的精确细胞功能尚待确定,但问题在于,旨在提高脑组织中脯氨酸内肽酶活性的药理学策略是否可能改善上述疾病患者的预后。